This project is developing novel, sensitive and animal-free cancer imaging probes as an effective replacement for antibody-based diagnostic reagents widely used in clinical laboratories. At present, most current clinical cancer diagnostic reagents are antibody based and rely on the use of animals. Antibodies are generated by injecting a specific target antigen into an animal host, which includes mice, rats, rabbits, goats, sheep, chickens or horses.
Dr Francis and her team have developed MRI as a replacement to animal techniques to study both the structure and function of healthy and diseased kidneys. Changes in kidney blood oxygenation and blood flow in healthy subjects and CKD patients will be measured using MRI and the findings will be compared with clinical measurements (blood samples and biopsies). Dr Francis aims to investigate whether MRI could be a reliable diagnostic tool for CKD.
This project developed an engineered in vitro model of wound healing and then used it to identify the factors that regulate wound closure. It established a novel platform that could replace many mouse studies and improve pre-clinical testing of drugs and therapeutics.
This research on schwannomas and meningiomas used a unique human cell culture model using cells derived from surgical patients. This has led to the identification and testing of new, targeted therapies and the team have successfully translated their research into early clinical trials. This approach has allowed them to screen approved drugs directly and go straight into clinical trials, avoiding pre-clinical animal trials.
Every year, 8% of the population will be diagnosed with chronic pain but only two-thirds will recover. By collecting human nerve stem cells from discarded human teeth, this project will increase our understanding of how inflammation affects the nerve cells in the face and how this can lead to chronic pain, whilst replacing the use of animals.
The Skin Research Tissue Bank (STB) at Glasgow Caledonian University currently supports several different projects in diabetic wound healing, vascular problems with diabetes, diabetic retinopathy and cellular ageing. Our funding will help the STB to develop new types of human cell models that can replace animal experimentation on rodents.
This research aims to understand the mechanisms that cause particular cells of the pancreas, beta cells, to lose their ability to produce insulin in those suffering from diabetes.
This project aims to assess the utility of induced pluripotent stem cells (iPSCs) as a relevant model system for the pre-clinical testing of novel therapies to target cancer stem cells, especially in leukaemia. Currently, scientists rely on animals, such as mice, for the early or preclinical development of novel therapies in cancer.
Dr Martin Garnett and his team at the University of Nottingham have made a substantial contribution to making studies of drug uptake across the gut lining more accurate and realistic than existing animal and human cell models.
Edentulousness – Developing a 3D organotypical model to assess skin and gum penetrating implant soft tissue outcomes and implant device development
The project’s objectives are to replace animal use in dental research by developing a 3D model of human gums that do not involve the use of any animal products. The model should be able to closely mimic the in vivo environment and model clinical outcomes for tooth root implants in vitro.